Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 12/20 | 0.70 |
| ▸ | ITGA2B | P08514 | 9/20 | 0.70 |
| ▸ | ITGAV | P06756 | 7/20 | 0.55 |
| ▸ | TGM2 | P21980 | 7/20 | 0.53 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | TGM6 | O95932 | 1/20 | 0.47 |
| ▸ | F13A1 | P00488 | 1/20 | 0.47 |
| ▸ | TGM1 | P22735 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27456656 | 0.84 | TGM2 (0.61) | ITGB3ITGA2BTGM2TGM6F13A1 | |
| SCHEMBL3961748 | 0.84 | TGM2 (0.61) | ITGB3ITGA2BTGM2TGM6F13A1 | |
| SCHEMBL7141576 | 0.82 | ITGB3 (1.00) | ITGB3ITGA2BITGAVITGB5 | |
| SCHEMBL7141583 | 0.82 | ITGB3 (1.00) | ITGB3ITGA2BITGAVITGB5 | |
| SCHEMBL8549663 | 0.82 | ITGB3 (0.47) | ITGB3ITGA2BTGM2 | |
| SCHEMBL29400646 | 0.81 | ITGB3 (0.57) | ITGB3ITGA2BITGAVTGM2CTSL | |
| SCHEMBL5130791 | 0.81 | ITGB3 (0.65) | ITGB3ITGA2BITGAVITGB5 | |
| SCHEMBL28703518 | 0.81 | ITGB3 (0.57) | ITGB3ITGA2BITGAVTGM2CTSL | |
| SCHEMBL5579946 | 0.81 | ITGB3 (0.65) | ITGB3ITGA2BITGAVITGB5 | |
| SCHEMBL3964344 | 0.81 | TGM2 (0.58) | ITGB3ITGA2BTGM2TGM6F13A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730672-B2 | PROTEASE INHIBITOR | ZENECA LIMITED (GB) | 2004-05-04 | — | — | US | disclosed |
| US-20020119968-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED | 2002-08-29 | — | — | US | disclosed |
| US-6225309-B1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED (GB) | 2001-05-01 | — | — | US | disclosed |
| US-5965559-A | STRONG INHIBITORY EFFECT AGAINST THE ACTIVATED COAGULATION PROTEASE KNOWN AS FACTOR XA; PREVENTION OF THE CLEAVAGE OF PROTHROMBIN TO THROMBIN; AMINO-SUBSTITUTED PYRIMIDINES AMIDINE GROUP-FREE | ZENECA LIMITED (GB) | 1999-10-12 | — | — | US | disclosed |
| EP-0783500-B1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LTD (GB) | 1998-07-22 | — | — | EP | disclosed |
| EP-0783500-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996010022-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1996-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119968-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | SERPINC1, F2, SULT1E1 | ITGB3 254/4885ITGA2B 708/4885ITGAV 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.